Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shengjing Capsule is a Traditional Chinese Medicine (TCM) formulation approved by the National Medical Products Administration (NMPA) of China for the treatment of male infertility. It is specifically indicated for conditions such as oligospermia (low sperm count), asthenospermia (low sperm motility), and spermatorrhea resulting from "kidney essence deficiency." The formula consists of 19 distinct components, including *Cornu Cervi Pantotrichum* (Deer Antler), *Radix Ginseng* (Ginseng), and *Fructus Lycii* (Wolfberry). Pharmacologically, it is thought to enhance spermatogenesis by modulating the hypothalamic-pituitary-gonadal (HPG) axis, increasing testosterone levels, and improving the antioxidant capacity of the testes. It is manufactured by several companies, most notably Guizhou Ensure Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shengjing capsule.